<DOC>
	<DOC>NCT01412177</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.</brief_summary>
	<brief_title>OTO-104 for the Treatment of Meniere's Disease</brief_title>
	<detailed_description />
	<mesh_term>Meniere Disease</mesh_term>
	<criteria>Subject has a diagnosis of unilateral Meniere's disease by 1995 American Academy of Otolaryngology â€” Head and Neck Surgery (AAOHNS) criteria and reports active vertigo for the 2 months prior to the study leadin period. Subject has experienced active vertigo during the leadin period. Subject has documented asymmetric sensorineural hearing loss. Subject agrees to maintain their current treatments for Meniere's disease while onstudy. Subjects currently on a lowsalt diet and/or diuretic at the time of screening agree to continue this treatment throughout the study. Subject is pregnant or lactating. Subject has a history of immunodeficiency disease. Subject has a history of previous endolymphatic sac surgery. Subject has a history of previous use of intratympanic (IT) gentamicin in the affected ear. Subject has a history of tympanostomy tubes with evidence of perforation or lack of closure. Subject has experienced an adverse reaction to IT injection of steroids. Subject has used an investigational drug or device in the 3 months prior to screening. Subject has previously been randomized to a trial of OTO104.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Meniere's Disease</keyword>
	<keyword>Vertigo</keyword>
	<keyword>Definitive vertigo</keyword>
	<keyword>Vertigo episodes</keyword>
	<keyword>Vertigo frequency</keyword>
	<keyword>Tinnitus</keyword>
	<keyword>Hearing loss</keyword>
	<keyword>Aural fullness</keyword>
</DOC>